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Abstract Hemolytic-uremic syndrome (HUS) is a leading
cause of acute renal failure in childhood. In its typical
presentation, it is preceded by an episode of diarrhea mostly
due to Shiga-toxin-producing Escherichia coli. There is
important geographical variation of many aspects of this
syndrome. Nationwide data on childhood HUS in Switzerland
have not been available so far. In a prospective national study
through the Swiss Pediatric Surveillance Unit 114 cases
(median age 21 months, 50% boys) were reported between
April 1997 and March 2003 by 38 pediatric units (annual
incidence 1.42 per 105 children ≤16 years). Shiga-toxin-
producing E. coli were isolated in 32 (60%) of tested stool
samples, serotype O157:H7 in eight. Sixteen children
presented with only minimal renal involvement, including
three with underlying urinary tract infection. Six patients
presented with atypical hemolytic-uremic syndrome, and six
with HUS due to invasive Streptococcus pneumoniae
infection. Mortality was 5.3%, including two out of six
children with S. pneumoniae infection. The severity of
thrombocytopenia and the presence of central nervous system
involvement significantly correlated with mortality. In con-
clusion, childhood HUS is not rare in Switzerland. Contrasting
other countries, E. coli O157:H7 play only a minor role in the
etiology. Incomplete manifestation is not uncommon.
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Abbreviations
HUS hemolytic-uremic syndrome
D+ HUS typical HUS (enteropathic or non-enteropathic)
D− HUS atypical HUS
cHUS complete HUS
iHUS incomplete HUS
Stx Shiga toxin
EHEC enterohemorrhagic Escherichia coli
NENT Swiss National Centre for Enteropathogenic
Bacteria
SPSU Swiss Pediatric Surveillance Unit
STEC Shiga-toxin-producing Escherichia coli
UTI urinary tract infection
CI confidence interval
Introduction
Childhood hemolytic-uremic syndrome (HUS) is not very
frequent but mostly a severe multisystem disorder charac-
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terized by microangiopathic hemolytic anemia, thrombocy-
topenia, and acute renal impairment. It is associated with
significant morbidity and mortality, including acute and
chronic renal failure and long-term multi-organ complica-
tions in a substantial number of affected children. In its
typical (D+ HUS), mostly enteropathic form, childhood
HUS occurs after a prodromal episode of usually bloody
diarrhea caused by a Shiga toxin (Stx)-producing pathogen,
most commonly enterohemorrhagic Escherichia coli (Stx-
producing EHEC = STEC), worldwide primarily of
serotype O157:H7. However, other serotypes are increas-
ingly reported [15, 25] as well. On average, enteropathic
HUS appears six (5–10) days after the onset of gastroin-
testinal symptoms and affects 3–9% (up to 20% in epidemic
forms) of infected children [3, 6]. Risk factors for the
development of HUS include young age, bloody diarrhea,
fever, elevated leukocyte count, elevated C-reactive protein,
as well as treatment with antimotility agents, antibiotics,
and non-steroidal anti-inflammatory drugs [1, 4, 8, 17, 36].
Elevated leukocyte count, severe gastrointestinal prodromi,
early anuria, and age below 2 years are considered
predictors of a severe course [26].
More rarely, STEC cause a typical, but non-enteropathic
HUS in the context of an extra-intestinal, mostly urinary
tract infection (UTI) [16, 29].
Finally, in some patients, the clinical presentation is not
related to diarrhea and/or Stx-producing pathogens; these
forms have formerly been referred to as atypical HUS
(D− HUS). The etiology of D− HUS is diverse, including
other infections, disorders of complement regulation, von
Willebrand proteinase deficiency, and more [5, 9, 10, 21]. As
infection with Streptococcus pneumoniae represents another
major infectious cause of non-Stx-associated HUS these cases
should be classified separately.
Despite these general characteristics, several studies
indicate important geographical variation of clinical, epide-
miological, and microbiological features of this syndrome.
So far, some single center data [18, 20], but no systematic
report on the characteristics of childhood HUS have been
available for Switzerland. This was the reason to undertake
this study between April 1997 and March 2003, using the
SPSU, an ongoing national surveillance system.
Methods
The SPSU was established in 1995 to assess epidemiological
and clinical features of selected rare childhood diseases
leading to hospitalization. It is operated under the auspices of
the Swiss Pediatric Society and the Swiss Federal Office of
Public Health. The surveillance period for HUS lasted from
April 1, 1997, to March 31, 2003. Cases were defined as
children ≤16 years of age with: (1) acute hemolytic anemia,
(2) microscopic evidence of red blood cell fragmentation, (3)
thrombocytopenia (platelet count ≤150×109/L), and (4)
acute renal impairment (urinalysis disclosing either (a) red
blood cells, cellular casts, and pathological proteinuria or
(b) dysmorphic red cells and pathological proteinuria, with
or without (c) creatinine levels above the upper limit of
normal for age, or an increase in creatinine of ≥50% above
baseline). HUS was diagnosed based on the presence of at
least three criteria or two criteria plus isolation of a Stx-
producing pathogen.
SPSU reply cards have been sent to all Pediatric Units of
Swiss Hospitals at monthly intervals. For each reported
case, the respective hospital was provided with a detailed
standardized questionnaire. Patients who did not meet the
case definitions were rejected. A follow-up questionnaire
was sent to the treating physician after 1 year.
Cases with preceding diarrhea (enteropathic) and/or
evidence of Stx-producing pathogens in cultures of stool,
urine, or blood were classified as typical HUS (D+ HUS).
Patients with S. pneumoniae-associated HUS were classi-
fied separately and the remaining non-Stx-associated cases
were referred to as atypical (D− HUS). HUS was moreover
referred to as complete (cHUS) in children who fulfilled the
above-mentioned serum creatinine definition of renal im-
pairment and as incomplete (iHUS) if the renal impairment
manifested only with proteinuria and/or hematuria or a mild
documented rise in serum creatinine level (<50% over
baseline). If available, stool samples of children with
enteropathic HUS were processed for STEC in the Swiss
National Center for Enteropathogenic Bacteria (NENT) [12].
Significance between groups was determined by Stu-
dent's t test, by one-way analysis of variance (ANOVA)
with Bonferroni multiple comparison post test, and
corresponding non-parametric tests as appropriate for
continuous, and Fisher's exact test for categorical variables.
Results are expressed as mean±standard deviation (SD) or
as median with range. Qualitative parameters are given as a
proportion (percentage). Two-sided tests were used
throughout, and P values<0.05 were considered statistically
significant.
Results
Between April 1997 and March 2003, all SPSU reply cards
and HUS questionnaires were returned (100%). A total of 114
HUS patients (median age 21 months; range 20 days to
13 years; 57 girls and boys, each) were identified. One hundred
patients (88%) were ≤5 years old. Typical and atypical HUS
accounted for 102 (89%) and six (5%) cases, respectively, and
in six (5%) patients HUS was due to invasive infection with S.
pneumoniae. The disease was complete in 98 (86%) and
incomplete in 16 (14%) children. The average annual
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incidence was 1.42 cases (range, 0.61–1.92) per 100,000
children ≤16 years of age.
Typical versus atypical and pneumococcal HUS
HUS was typical in 102 children, including 99 with enter-
opathic and 3 with non-enteropathic forms as a consequence
of a STEC-associated UTI. In contrast to typical HUS, which
predominantly occurred during the warm season with 70/102
cases (69%) diagnosed between May and September, nine of
12 atypical and S. pneumoniae-associated cases (75%)
occurred between October and April (P<0.01).
STEC were isolated in 32/53 stool samples (60%)
examined by the NENT. In three children with UTI-
associated HUS, STEC were isolated from the urine and
also from a blood culture in one. Eighteen different serotypes
were identified, including O157:H7 in eight, O145:H25 in
five, O26:H11 in four, and O55:H7 in three samples; the
remaining 14 serotypes were identified only once or twice,
each. Although serotype O157:H7 was the most frequently
isolated serotype, it only accounted for eight of 35 (23%)
classified pathogens. In 11 additional children with typical,
enteropathic HUS STEC were identified by private labora-
tories but not further differentiated.
There was no association between isolation of E. coli
O157:H7 and presentation or clinical course of the disease.
Bloody diarrhea was present in 75% of those with and 46%
of those without O157:H7 isolation, respectively. Dialysis
became necessary in 13% and 39% of these groups,
respectively. There was no fatality among children with
O157:H7 isolation. O157:H7 was even found in one patient
with incomplete HUS, however, complicated by severe
intussusception in this case.
Shiga toxin production was documented in 37 of 102
patients with D+ HUS. Unfortunately, the number of samples
being tested for Stx is not known. Stx1 was found in seven,
Stx2 in 23, and both in seven patients. There was no association
of either type with complete or incomplete forms of the disease.
In six children the disease was the consequence of an
infection with S. pneumoniae. In one previously reported
patient the disease complicated an acute infectious mono-
nucleosis [28], while in two patients atypical HUS occurred
as a consequence of cobalamin C disease and factor H
deficiency, respectively. Classification was not possible in
the remaining three patients.
Complete versus incomplete HUS
Hemolytic-uremic syndrome was incomplete in 16/114
(14%) patients. They presented with acute hemolytic
anemia, evidence of red blood cell fragmentation, and
altered urinalysis. Thrombocytopenia was present in 12
children. However, these children did not fulfill the case
definition with regard to their serum creatinine levels.
Hemolytic-uremic syndrome was typical in 14 patients with
iHUS, including 11 with enteropathic forms (bloody diarrhea
in five) and three with UTI. Duration of prodromal diarrhea
was longer in iHUS compared to cHUS (10 days versus
5 days, P<0.01). STEC were isolated in five of seven
examined fecal specimens (serotype O157:H7 in one case),
both not significantly different from cHUS. Private labora-
tories disclosed Shiga-toxin-producing E. coli in two further
children. No stool sample was available in two cases with an
incomplete form of enteropathic HUS. Additionally, in
children with iHUS anemia and thrombocytopenia were
significantly (P<0.01) less pronounced than in children with
cHUS (Table 1). Accordingly, blood transfusions were
significantly less often needed (P<0.01) in patients with
iHUS as compared to those with cHUS. Finally (Table 1),
in iHUS the duration of hospital stay was significantly
shorter compared to survivors with cHUS (9 versus
16 days, P<0.01) and neurological involvement was less
frequent (P<0.05). One girl with O157:H7-associated iHUS
developed intussusception requiring surgical intervention.
HUS associated with urinary tract infection
The causative infection was localized in the urinary tract in
three children with iHUS. All presented with an acute
febrile UTI without any evidence of an intestinal infection.
These patients presented with microangiopathic hemolytic
anemia and thrombocytopenia; two of them additionally
with arterial hypertension. An underlying malformation of
the urinary tract was found in one patient.
Mortality
Six patients died (Table 2), corresponding to an overall
mortality of 5.3%. All had suffered from cHUS. None of
the patient with atypical HUS (D−) died. A causative
infectious agent was identified in three children (S.
pneumoniae in two, STEC in one). The highest mortality
(2/6=33%) was observed for HUS associated with invasive
S. pneumoniae infection (P<0.05). Five of the six patients
with a fatal outcome (83%) had suffered from severe
neurological symptoms, as compared to 18% of survivors
with cHUS. Thus, in the presence of severe neurological
symptoms, the relative risk of fatal outcome was 17.3 (95%
CI, 2.1–140.3, P<0.01). In contrast to the survivors with
cHUS (platelet count, 46±45×10E9/l), patients who died
presented with more severe thrombocytopenia (platelet
count, 12±10×10E9/l; P<0.01). Using arbitrary cut-offs
in these patients, thrombocytopenia below 20×10E9/l and
below 12×10E9/l were associated with a relative risk for
fatal outcome of 10.5 (95% CI, 1.3–86.0, P<0.05) and 14.0
(95% CI, 2.9–68.4, P<0.01), respectively.
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One-year follow-up
Of a total of 108 survivors, 80 (74%) had a reported 1-year
follow-up examination, including 74/98 (76%) of the D+
HUS, four of six (67%) of the D− HUS, and two of four
(50%) of the S. pneumoniae groups, respectively.
Among the children with D+ HUS persistent renal
impairment was reported for 13 (18%) and end-stage renal
failure requiring dialysis for four (5%) children. Twelve
patients (16%), including five with normal renal function,
suffered from persistent arterial hypertension. One patient
had persistent hematuria. Other complications were recurrent
bloody diarrhea in four (5%) and seizures in three patients
(4%; all with renal impairment). Rare complications such as
endocrine and exocrine pancreatic insufficiency with
insulin-dependent diabetes, reactive arthritis after an E. coli
0157:H7 infection and cardiomyopathy (with end-stage
renal failure) were noted in one patient, each. One patient
presented with residual hemiplegia in consequence of carotid
artery thrombosis during the acute phase. Another patient
was subject to laser therapy because of retinal bleeding.
In the subgroup of D− HUS two patients (50%) were in
end-stage renal failure (P<0.05, compared to D+ HUS), one
suffered from HUS relapses. Two children (50%) were
treated for isolated arterial hypertension. No other rare
complications were reported. No sequelae were reported by
the two patients with S. pneumoniae-associated HUS.
Ten questionnaires were received from patients who
initially suffered from iHUS (n=16). The only long-term
consequence reported by these patients was recurrence of
bloody diarrhea in one case.
Clinical and laboratory presentation during the acute
phase was similar in children with normal renal function at
follow-up, compared to those with chronic kidney disease
and reduced glomerular filtration after 1 year.
Only the need for transfusion was significantly associ-
ated with reduced renal function at 1 year (P<0.05); for the
duration of dialysis (39±38 versus 10±4 days) and the
incidence of seizures (31% versus 10%) during the acute
phase, the respective figures remained just below statistical
significance (P=0.06 for both).
Discussion
Hemolytic-uremic syndrome was first described by Gasser
and coworkers in 1955 in Switzerland [14]. However,
except some single center studies [18, 20], nationwide data
on childhood HUS in Switzerland have not been available
so far. This report summarizes the results of the first
Table 2 Clinical and laboratory data in six patients with fatal outcome from hemolytic-uremic syndrome
Total Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Presentation D+ D+ D+ S. pneumoniae S. pneumoniae D+
Age (months) Median 21 3 11 15 26 56 58
Sex Male Female Female Female Female Female
Pathogen STEC N 1 O145:H25 Yes Yes
S. pneumoniae N 2
Prodromi Diarrhea N 5 Yes Yes Yes No Yes Yes
Bloody diarrhea N 2 No Yes No No No Yes
Respiratory tract
infection
N 4 No No Yes Yes Yes Yes
Fever N 3 No No Yes Yes Yes No
Symptoms/laboratory
tests
Hemoglobin (g/l) Median 61 40 117 12 40 81 111
Platelets (x10E9/l) Median 9 4 31 8 6 10 14
Plasma creatinine
(µmol/l)
Median 291 437 295 252 199 237 270
Oliguria N 6 Yes Yes Yes Yes Yes Yes
Anuria N 5 Yes Yes Yes No Yes Yes
Arterial hypertension N 3 Yes No Yes No Yes No
Neurological symptoms N 5 Seizure Comma Seizure – Disoriented Seizure
Cerebral CT imaging Ischemic
encephalopathy
Cortical
necrosis
Edema,
bleeding
Edema,
meningitis
Infarction
Treatment Packed red cells
transfusion
N 5 Yes Yes Yes Yes Yes No
Dialysis N 5 PD PD PD/HD No No PD
PD peritoneal dialysis, HD hemodialysis; for abbreviations of D+ HUS, D− HUS, and S. pneumoniae, please see footnote Table 1
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nationwide prospective cross-sectional study performed
between April 1997 and March 2003 using the SPSU
network. In addition to the widely established features [25],
this study reveals some particular aspects of childhood
HUS: enterohemorrhagic E. coli of serotype O157:H7 only
play a minor role in etiology of HUS in Switzerland, and
infection with this strain is not associated with the most severe
courses of the disease. Fourteen percent of the patients
presented with only minor renal involvement, including three
patients in whom HUS was caused by a STEC-associated
UTI. Finally, the degree of thrombocytopenia and severe
neurological symptoms were significantly associated with the
risk of fatal outcome, whereas young age was not associated
with the severity of the disease.
HUS is associated with significant morbidity and mortality
during the acute phase. It is a leading cause of acute renal
failure and results in long-term renal and extra-renal compli-
cations in a substantial number of affected children. It consists
of a heterogeneous group of hemolytic disorders and new
insights into pathophysiology have demonstrated, that HUS
represents one clinical manifestation of a broader spectrum
referred to as thrombotic microangiopathy [31], characterized
by injury to the vascular endothelium which can be triggered
by a number of different etiologies. Our survey primarily
focused on the description of epidemiological and clinical
aspects of HUS in Switzerland, whereas rare etiologies of the
disease in D− HUS were not systematically tracked.
Furthermore, we chose the traditional classification into D+
and D− forms of the disease for the presentation of our data
in order to allow comparison with data from other countries.
Patients with S. pneumoniae-associated HUS were classified
separately as a third group.
In accordance with most published reports [2, 15, 26],
the presentation of HUS in this study was typical (D+ HUS)
in the majority of the patients (89%); these cases occurred
significantly more often during summertime. Nevertheless,
EHEC were successfully isolated and characterized in only
60% of tested stool samples, an observation that has
previously been reported. In addition to technical difficul-
ties to identify EHEC serotypes [7], it is assumed that at
clinical onset of HUS, the causative agent has started to
disappear from the intestine resulting in negative stool
samples in many patients [30]. In North America and
worldwide O157:H7 is the predominant serotype of EHEC
causing HUS [2]. However, in Australia [11], Germany, and
Austria [15] non-0157 STEC strains were more common.
In our study, we found similar results with O157:H7
accounting for only eight (25%) of 32 positively tested
stool samples and eight of 53 (15%) of all tested specimens
respectively [19], underlining the increasingly acknowl-
edged burden of disease associated with non-O157 STEC.
Additionally, it is evermore recognized that illness due to
non-O157 STEC may be equivalent in severity to illness
induced by E. coli O157:H7. Accordingly, in the present
study we found no association between isolation of E. coli
O157:H7 and presentation or clinical course of the disease.
In our database, 86% of the patients had major renal
involvement (cHUS), 47% required dialysis, and 65%
received packed red cell transfusion, data similar to
previous reports [2, 15, 26]. It has been described that
some patients develop hemolytic anemia and thrombocyto-
penia with little evidence of renal disease, whereas other
children present with important renal disease comparatively
associated with few hematological abnormalities [32]. The
present study clearly reveals a distinct subgroup of patients
with only minor renal involvement. These 14% of patients,
referred to as suffering from iHUS (Table 1), also presented
with significantly less pronounced hematological abnor-
malities and therefore less need for transfusion, less
neurological involvement, and shorter duration of hospital-
ization. In contrast, prodromal diarrhea lasted significantly
longer compared to patients with cHUS, presumably
reflecting a less severe multisystem involvement. Otherwise
there were no differences in frequency of bloody diarrhea
or causative serotypes of E. coli between the two groups.
The observed proportion of iHUS is likely to represent an
underestimate since many such patients, especially in case
of even milder forms are unlikely to reach the hospital, or
even to be diagnosed. Of note, in a prospective study in
Argentina the incidence of iHUS complicating bloody
diarrhea was twice that of cHUS [22]. This is of particular
importance because long-term follow-up examinations will
be missed in unrecognized cases. There are only few reports
describing the various features of iHUS, even in large
surveys of cHUS; additionally the case definitions were not
universally the same [22, 23, 33]. In rare cases, HUS can
originate from UTI [16,29]; in three patients of this series,
iHUS was consequence of a STEC-associated UTI. Some
authors have suggested that antibiotics may aggravate
enteropathic HUS [36]. In contrast, prompt initiation of
antibiotic treatment is certainly crucial for a favorable
outcome in STEC-associated UTI with consecutive HUS.
In a minority of patients, the clinical presentation of
HUS is atypical (D− HUS), i.e. not related to enterocolitis
and/or STEC-infection. The etiology of D− HUS is diverse,
including infectious causes such as HIV and more rarely
other viral agents, genetic abnormalities of complement
regulatory proteins (complement factor H, I, B, or MCP),
and von Willebrand proteinase deficiency [5, 9, 10, 21, 24,
35]. In this survey, six patients (5%) presented with D−
HUS, and six patients had HUS due to S. pneumoniae
infection. This figure is slightly higher than in other studies,
which reported this association for 38–43% of non-STEC
HUS [10]; this might support the impression of an
increasing incidence of S. pneumoniae-associated HUS
[34]. Other identified causes of D− HUS in this series were
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cobalamin C disease, factor H deficiency, and infectious
mononucleosis in one patient each; for the remaining
patients, the origin remained unexplained.
Many studies addressed the short- and long-term course
and outcome of HUS. In summary, it is assumed that death
or end-stage renal disease occurs in about 12% of D+ HUS
and 25% of survivors demonstrate long-term renal sequelae
[13], whereas prognosis in non-Stx-associated HUS seems
to be even worse. Given the important methodological
differences between studies, comparison proves difficult
and the subject still remains controversial [13]. Age under
2 years [8], HUS due to E. coli O157:H7 [15], high
leukocyte count [15, 17], D− and pneumococcal HUS [9,
25], central nervous symptoms [13, 27], and the need of
dialysis during the acute phase [13] have all been associated
with a severe course and a worse long-term prognosis,
respectively. We report on a highly significant association
between both, severe thrombocytopenia and central nervous
manifestations, with risk of death during the acute phase
and a significant association between both, the need for
transfusion and the long-term prognosis (renal function).
Additionally, we observed a tendency towards worse
outcome with signs of chronic kidney disease or even
end-stage renal disease in children with longer duration of
dialysis and in those with seizures. The small number of
patients certainly prohibits firm interpretation of these
observations and, therefore, further studies are mandatory.
The overall mortality in this series was 5.3%, similar to 3–5%
reported in the literature [15, 25, 26]. Compared to D+ HUS
(4%), children with pneumococcal HUS (33%) had a
significantly higher mortality (P<0.05), supporting the
results of other studies that suggest a more severe acute
course of HUS due to S. pneumoniae [10, 34]. Children with
iHUS showed no renal sequelae at 1 year after the acute
disease. Whether this holds true for the long-term prognosis
remains to be studied. In their review, Garg et al. [13] found
an association between the severity of the acute illness and
an adverse long-term outcome in children with D+ HUS.
However, these authors found also several studies suggesting
that patients with less severe forms of HUS may still
demonstrate renal sequelae at follow-up, in several even
after apparent complete recovery from acute HUS. These
observations emphasize the necessity of long-term follow-up
after HUS, even in case of mild acute disease or initial
apparent complete recovery. Therefore, unless other data
become available, we suggest, that children with iHUS also
deserve careful long-term follow-up. In order to recruit these
children for appropriate care, the awareness of these mild
forms of HUS needs to be increased.
Taking the limitations of the cross-sectional design of this
study, i.e. the limited number of patients and the short follow-
up period, into account, we conclude that this first, prospective,
national study on childhood HUS in Switzerland establishes
robust clinical, epidemiological, and bacteriological data,
emphasizing the need for further long-term studies, especially
to identify children at risk for long-term sequelae after minor
renal involvement or initial apparent complete recovery of
acute disease.
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